{"id":"W2135939943","doi":"10.1200/jco.2007.15.8808","title":"Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; EGFR inhibitors; Endometrial cancer; Erlotinib Hydrochloride; Cancer; Chemotherapy; Progressive disease; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003090328,0.0001945301,0.003152967,0.0006550117,0.00005117104,0.000002432604,0.0002182968,0.000191849,0.0008247095],"category_scores_gemma":[0.01165148,0.0001151084,0.0005239111,0.001260582,0.0001761506,0.00009811373,0.00008328272,0.001056426,0.000005920845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000326199,"about_ca_system_score_gemma":0.00275937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002737192,"about_ca_topic_score_gemma":0.0005291393,"domain_scores_codex":[0.9934573,0.0008812423,0.004335452,0.0002509627,0.0007810607,0.0002939411],"domain_scores_gemma":[0.9915667,0.004849471,0.002477112,0.0002026627,0.0004433065,0.0004607579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1636889,0.1292845,0.09850416,0.00006624532,0.001725754,0.005216379,0.001034111,0.00001652804,0.00007178335,0.00001077003,0.001082742,0.5992982],"study_design_scores_gemma":[0.3583527,0.5271677,0.09575962,0.0002000333,0.001614424,0.000468354,0.0006557205,0.00001798336,0.0001733,0.0001020501,0.01533351,0.0001545561],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932984,0.001635696,0.00001035968,0.001052928,0.002716822,0.0008033956,0.00001380816,0.000006015885,0.0004625643],"genre_scores_gemma":[0.9940725,0.003239274,0.0007336837,0.0004363576,0.001264549,0.00002799877,0.000002149073,0.00001638015,0.0002071305],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5991436,"threshold_uncertainty_score":0.9966738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.382469676198411,"score_gpt":0.5661995313252967,"score_spread":0.1837298551268856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}